Last updated: September 9, 2026
Sodium nitrite and sodium thiosulfate have two distinct pharmaceutical markets. Their combined use in cyanide poisoning is a small, procurement-driven antidote market led by Nithiodote and generic hospital-stock products. Sodium thiosulfate has a larger commercial opportunity in pediatric oncology through Pedmark, Fennec Pharmaceuticals’ branded product for reducing cisplatin-induced ototoxicity.
The principal market conclusions are:
- Cyanide-antidote demand is recurring but limited, with sales influenced by government stockpiles, hospitals, emergency-response agencies, and product availability.
- Sodium thiosulfate has greater revenue potential than sodium nitrite because Pedmark is a specialty oncology product with broader hospital use and higher pricing.
- Nithiodote faces generic and institutional procurement pressure, while Pedmark’s risk is concentrated in reimbursement, clinical adoption, patent enforcement, and potential competition from compounded or alternative sodium thiosulfate products.
- The financial trajectory is asymmetric: sodium nitrite is a low-growth, supply-sensitive product; sodium thiosulfate has a growth profile tied to pediatric cancer treatment volumes and penetration of supportive-care protocols.
What pharmaceutical products contain sodium nitrite and sodium thiosulfate?
Sodium nitrite and sodium thiosulfate are used together as an intravenous cyanide antidote. Sodium nitrite induces methemoglobinemia, allowing cyanide to bind methemoglobin rather than inhibit mitochondrial cytochrome oxidase. Sodium thiosulfate supplies sulfur for conversion of cyanide to thiocyanate, which is eliminated in urine.
The principal U.S. branded combination is Nithiodote, marketed by Hope Pharmaceuticals. The product is supplied as separate sodium nitrite and sodium thiosulfate components that are administered sequentially. The FDA approved Nithiodote in 2011 under the 505(b)(2) pathway for acute cyanide poisoning [1].
Sodium thiosulfate is also marketed separately as Pedmark, a preservative-free intravenous formulation approved by the FDA in September 2022. Pedmark is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged one month and older with localized, nonmetastatic solid tumors [2].
| Product |
Active ingredient |
Primary indication |
Sponsor or commercial owner |
Market type |
| Nithiodote |
Sodium nitrite plus sodium thiosulfate |
Acute cyanide poisoning |
Hope Pharmaceuticals |
Emergency antidote |
| Generic sodium nitrite injection |
Sodium nitrite |
Cyanide poisoning, generally with thiosulfate |
Multiple manufacturers |
Generic hospital product |
| Generic sodium thiosulfate injection |
Sodium thiosulfate |
Cyanide poisoning and other hospital uses |
Multiple manufacturers |
Generic injectable |
| Pedmark |
Sodium thiosulfate |
Cisplatin-associated ototoxicity in pediatric solid tumors |
Fennec Pharmaceuticals |
Specialty oncology |
Sodium thiosulfate also has nonapproved or noncentral uses in nephrology, dermatology, calciphylaxis management, and certain investigational oncology protocols. Those uses create clinical awareness but do not have the same regulatory pricing structure as Pedmark.
How large is the sodium nitrite and sodium thiosulfate market?
The market is fragmented and is not reported as a single transparent category. Public financial disclosure generally does not separate sodium nitrite revenue from sodium thiosulfate revenue, and generic hospital sales are not disclosed by active ingredient in a consistent manner.
The market has three economic pools:
- Cyanide-antidote products used by hospitals, emergency departments, industrial employers, military organizations, and public-health agencies.
- Government and institutional stockpiles maintained for chemical-exposure preparedness.
- Pediatric oncology use of branded sodium thiosulfate through Pedmark.
The cyanide-antidote market is demand-stable but volume constrained. Cyanide poisoning is uncommon, so routine commercial consumption is low. Buyers purchase for readiness rather than frequent administration. This creates inventory cycles, tenders, expiration-related replacement demand, and occasional shortages.
Pedmark has a different demand model. Its addressable market depends on:
- The number of pediatric patients receiving cisplatin.
- The proportion of patients with tumors for which Pedmark is clinically appropriate.
- Hospital adoption of ototoxicity-prevention protocols.
- Payer reimbursement.
- Physician confidence in preserving hearing without compromising antitumor efficacy.
- Availability of pediatric oncology infusion capacity.
The commercial value per treated patient is materially higher for Pedmark than for generic sodium thiosulfate used as an antidote. This makes Pedmark the main source of potential pharmaceutical-sector revenue growth for sodium thiosulfate.
What is the financial trajectory for sodium nitrite products?
Sodium nitrite revenue is likely to remain modest and procurement-driven. Its financial performance is shaped by supply continuity and contract wins rather than by expanding therapeutic utilization.
Nithiodote benefits from several commercial characteristics:
- It addresses a life-threatening emergency.
- Hospitals and government agencies must maintain inventory.
- The product has a recognized FDA indication.
- Substitution can be operationally difficult during an emergency.
- Demand can rise when regulators or public-health agencies increase preparedness requirements.
The constraints are equally important:
- Low annual treatment volumes.
- Generic competition.
- Institutional purchasing pressure.
- Expiration and inventory-management costs.
- Potential substitution with hydroxocobalamin, including Cyanokit, where clinicians prefer a product that does not induce methemoglobinemia.
Sodium nitrite can worsen oxygen-delivery problems in patients with smoke inhalation, anemia, or certain cardiopulmonary conditions. This safety consideration can favor hydroxocobalamin in some cases, particularly when the diagnosis is uncertain or smoke inhalation is present [3].
The result is a defensive market rather than a high-growth market. Revenue can be volatile by quarter because a single government contract or hospital-system tender may materially affect sales. Long-term growth is more likely to come from price increases, contract retention, and supply reliability than from an increase in poisoning cases.
What is the financial trajectory for Pedmark sodium thiosulfate?
Pedmark is the principal growth asset in this product group. Fennec Pharmaceuticals launched the product in the United States after the 2022 FDA approval and has focused commercialization on pediatric oncology centers.
Pedmark’s revenue trajectory depends on market penetration rather than disease prevalence alone. The product entered a specialized market in which treatment protocols, hospital formularies, and reimbursement systems must change before sales can expand.
| Financial driver |
Effect on Pedmark |
| Pediatric cisplatin volume |
Sets the underlying patient pool |
| FDA-approved indication |
Supports formulary adoption and payer discussions |
| Specialty sales infrastructure |
Enables access to a concentrated number of oncology centers |
| Reimbursement |
Determines treatment availability and hospital willingness to stock |
| Ototoxicity monitoring |
Can increase awareness of hearing-preservation needs |
| Treatment timing |
Requires administration during the cisplatin treatment course |
| Clinical-site protocols |
Can accelerate or delay adoption |
| Competition from nonbranded sodium thiosulfate |
Creates price and substitution pressure |
Fennec’s public filings describe Pedmark as its commercial product and identify product sales, gross margin, selling expenses, and market-access spending as the main drivers of its financial profile [4]. The company’s trajectory is therefore more sensitive to adoption rates and operating leverage than to raw market expansion.
Pedmark has the potential to move from launch-stage losses toward improved operating leverage if sales grow faster than commercial and medical-affairs costs. The key financial risk is that the pediatric oncology market is concentrated and adoption can be gradual. A specialty product can generate strong revenue per patient while still requiring substantial spending to secure reimbursement and change clinical practice.
What patents protect sodium nitrite, sodium thiosulfate, Nithiodote, and Pedmark?
Patent protection differs sharply between the emergency antidote market and the pediatric oncology market.
Nithiodote is a combination product composed of long-established active ingredients. Its competitive protection is therefore less dependent on composition-of-matter patents and more dependent on formulation, packaging, regulatory status, manufacturing controls, and supply reliability. The FDA approval was granted under section 505(b)(2), a pathway that permits reliance in part on existing information while supporting approval of a modified product or presentation [1].
Pedmark has a stronger commercial protection profile because its value depends on a specific formulation, indication, dosing regimen, and pediatric oncology use. Its patent and regulatory position can include:
- Patents covering sodium thiosulfate formulations.
- Patents covering use to prevent or reduce cisplatin-associated ototoxicity.
- Patents covering dosing or administration timing.
- FDA regulatory exclusivity associated with the pediatric indication.
- Orphan-drug or pediatric regulatory incentives, where applicable.
- Manufacturing and quality-control know-how for a preservative-free injectable product.
Patent scope must be assessed through the current FDA Orange Book, USPTO records, and litigation docket. Patent expiration dates can vary by patent term adjustment, patent-term extension, terminal disclaimers, and listing updates. A simple active-ingredient search is not sufficient because sodium thiosulfate is an old compound with limited composition-of-matter protection.
The practical distinction is clear: Nithiodote’s barriers are primarily regulatory and supply-chain based, while Pedmark’s barriers include formulation, use patents, pediatric clinical data, manufacturing, and commercial execution.
What is the Orange Book status of Nithiodote and Pedmark?
The Orange Book is the principal U.S. source for listed patents and exclusivity associated with approved drug products [5]. For these products, the commercially relevant review should cover:
- Whether the product has listed patents.
- Whether patents cover the formulation, method of use, or both.
- Whether any listing has expired.
- Whether a generic applicant has submitted a Paragraph IV certification.
- Whether FDA approval is blocked by unexpired regulatory exclusivity.
- Whether a generic applicant can design around the listed claims.
Nithiodote’s combination of old active ingredients limits the value of composition patents. Any listed protection is more likely to involve the particular product presentation or method of use. Generic entry risk is therefore meaningful if an applicant can match the required dosage form, sterility, labeling, and stability profile.
Pedmark’s Orange Book analysis is more commercially important. A challenger would need to evaluate whether it can market sodium thiosulfate for the same pediatric ototoxicity indication without infringing method-of-use or formulation claims. A generic could potentially enter for an unprotected indication while carving out a protected use, depending on the scope of the approved label and the relevant claims.
When does sodium nitrite or sodium thiosulfate lose exclusivity?
Sodium nitrite and sodium thiosulfate do not have a single exclusivity date because the products and regulatory protections differ.
| Protection type |
Nithiodote |
Pedmark |
| Active-ingredient exclusivity |
Limited because ingredients are old |
Limited for sodium thiosulfate itself |
| Product-specific patents |
Potentially relevant |
Potentially material |
| Method-of-use patents |
Possible for cyanide treatment |
Central to pediatric ototoxicity protection |
| New-drug exclusivity |
Depends on FDA approval pathway and designation |
Depends on the approval and designation history |
| Pediatric exclusivity |
May apply if FDA requirements were met |
Potentially relevant depending on FDA designation |
| Generic entry |
Possible after regulatory and patent barriers clear |
More dependent on label, patent, and formulation strategy |
No reliable business conclusion should be based solely on the age of sodium thiosulfate or sodium nitrite. Generic entry depends on the approved product, listed patents, labeling, manufacturing requirements, and the challenger’s regulatory strategy.
Which companies are challenging sodium nitrite and sodium thiosulfate products?
The market has not developed the same visible Paragraph IV litigation pattern as large chronic-care drugs. Generic manufacturers can enter through abbreviated new drug applications or other regulatory routes without creating a major public litigation record before launch.
Potential competitors include:
- Generic injectable manufacturers.
- Hospital-compounding pharmacies, subject to applicable FDA requirements.
- Suppliers of alternative cyanide antidotes, especially hydroxocobalamin.
- Developers of alternative otoprotective agents.
- Manufacturers of sodium thiosulfate products approved for other indications.
For Nithiodote, the most credible commercial challenge is a lower-cost generic or institutional product. For Pedmark, the relevant challenge is a product that matches the pediatric use, preservative-free injectable requirements, dosing, and evidence expectations.
What litigation and settlement risks affect the market?
Litigation risk is more significant for Pedmark than for sodium nitrite because the commercial value of a pediatric oncology indication can support patent enforcement.
Potential disputes may involve:
- Paragraph IV certifications against listed patents.
- Claims that a generic label induces infringement.
- Patent validity challenges based on prior art concerning sodium thiosulfate and cisplatin ototoxicity.
- Patent-enablement and written-description challenges.
- Formulation equivalence.
- Regulatory exclusivity and pediatric labeling.
- Supply or licensing arrangements with manufacturers.
A settlement could delay generic entry while permitting an authorized generic or a limited launch date. The financial effect would depend on the agreed entry date, royalty structure, and whether the generic receives a licensed formulation or merely a delayed market-access right.
The absence of a highly visible litigation docket does not eliminate future risk. The product’s commercial value increases the incentive to challenge protection as sales mature.
What manufacturing and intellectual-property barriers affect generic entry?
Sterile injectable manufacturing is a meaningful barrier for both product groups. A competitor must demonstrate:
- Sterility assurance.
- Container-closure integrity.
- Stability through the labeled shelf life.
- Consistent concentration and pH.
- Compatibility with the administration system.
- Control of impurities and degradation products.
- Reliable supply of pharmaceutical-grade raw materials.
Nithiodote has added operational complexity because sodium nitrite and sodium thiosulfate must be supplied and administered in the correct sequence. Packaging, labeling, and emergency-use instructions affect substitution.
Pedmark requires a preservative-free pediatric injectable formulation and must fit into cisplatin treatment workflows. Manufacturing reliability is particularly important because pediatric oncology centers may resist switching products if a shortage could interrupt scheduled chemotherapy.
These barriers do not guarantee durable pricing. They can delay entry and reduce the number of credible competitors, but hospital procurement departments may still push prices lower once multiple suppliers qualify.
How does sodium thiosulfate compare with hydroxocobalamin?
Hydroxocobalamin is the main alternative cyanide antidote. It has a different mechanism and safety profile.
| Factor |
Sodium nitrite plus sodium thiosulfate |
Hydroxocobalamin |
| Mechanism |
Methemoglobin formation plus sulfur donation |
Cyanide binding |
| Oxygen-delivery concern |
Sodium nitrite can cause methemoglobinemia |
Does not rely on methemoglobin |
| Smoke-inhalation setting |
May be less attractive in some patients |
Often preferred when smoke inhalation is suspected |
| Product complexity |
Two active components |
Single principal antidote component |
| Market position |
Established, lower-cost alternative |
Strong emergency-use position |
| Supply economics |
Procurement and stockpile driven |
Higher-value emergency product |
The choice between products is clinical, but the commercial effect is material. When emergency departments favor hydroxocobalamin, sodium nitrite and sodium thiosulfate remain primarily stockpile and formulary products rather than high-volume treatment products [3].
What generic launch scenarios exist?
Three launch scenarios are most relevant.
Scenario 1: Generic cyanide-antidote entry
A generic sodium nitrite or sodium thiosulfate product enters through hospital channels. Pricing declines, but branded supply may remain viable where hospitals value packaged convenience, established procurement contracts, or continuity of supply.
Scenario 2: Limited-label sodium thiosulfate competition
A competitor markets sodium thiosulfate for a non-Pedmark indication or seeks approval that excludes the protected pediatric ototoxicity use. This could affect hospital purchasing indirectly while limiting direct substitution.
Scenario 3: Direct Pedmark challenge
A competitor files an ANDA or other application targeting the pediatric ototoxicity indication. The timing would depend on listed patents, regulatory exclusivity, patent certifications, and any litigation settlement.
The most probable near-term pressure is generic competition in cyanide antidotes. The most important long-term value event is a successful defense of Pedmark’s pediatric use and formulation protection.
What is the geographic coverage and commercial outlook?
The United States is the central commercial market because Pedmark has FDA approval and Fennec has built a U.S. specialty oncology business. International expansion requires separate regulatory approvals, reimbursement negotiations, and distribution partnerships.
For sodium nitrite and sodium thiosulfate antidotes, geographic demand is linked to:
- Industrial chemical exposure risk.
- National emergency-preparedness policy.
- Military procurement.
- Hospital stocking requirements.
- Availability of alternative antidotes.
For Pedmark, international opportunity depends on pediatric cisplatin use and local standards for hearing preservation. Markets with centralized pediatric oncology systems may be efficient to access but can impose aggressive price controls.
Key Takeaways
- Sodium nitrite is a mature, low-volume emergency-antidote market with procurement-driven revenue.
- Sodium thiosulfate has a higher-growth segment through Pedmark, approved for pediatric cisplatin-associated ototoxicity.
- Nithiodote’s competitive position depends on supply reliability, packaging, regulatory status, and government or hospital contracts.
- Pedmark’s value depends on adoption, reimbursement, clinical protocols, formulation protection, and method-of-use patents.
- Generic entry risk is higher for cyanide-antidote products than for the protected pediatric oncology use.
- Hydroxocobalamin is the principal clinical and commercial alternative to sodium nitrite plus sodium thiosulfate.
- The market’s most important financial variable is Pedmark penetration, not growth in cyanide-poisoning incidence.
- Sterile injectable manufacturing and pediatric oncology distribution create practical barriers, but they do not eliminate eventual price competition.
FAQs
Is sodium thiosulfate a high-revenue pharmaceutical ingredient?
The ingredient itself is low-cost and widely available. Revenue is higher when sodium thiosulfate is incorporated into a regulated, branded product such as Pedmark with a specific pediatric oncology indication.
Does Nithiodote have strong patent protection?
Nithiodote relies less on active-ingredient exclusivity because sodium nitrite and sodium thiosulfate are old compounds. Its protection is more closely tied to product presentation, regulatory status, manufacturing, and supply contracts.
Can generic sodium thiosulfate replace Pedmark?
A generic product may not be substitutable for Pedmark if it lacks the same formulation, labeling, pediatric indication, manufacturing specifications, or reimbursement status. Substitution depends on FDA approval and the scope of applicable patent claims.
Why is Pedmark commercially important if sodium thiosulfate is inexpensive?
Pedmark’s value comes from its approved use, pediatric clinical evidence, preservative-free injectable formulation, specialty distribution, and integration into cisplatin treatment protocols rather than from the raw-material cost.
What is the main investment risk for companies selling these products?
For cyanide-antidote products, the main risks are low utilization, generic pricing, contract volatility, and supply interruptions. For Pedmark, the main risks are slower-than-expected adoption, reimbursement friction, patent challenges, and the cost of building a specialty oncology commercial infrastructure.
References
- U.S. Food and Drug Administration. (2011). Nithiodote sodium nitrite and sodium thiosulfate injection: Prescribing information.
- U.S. Food and Drug Administration. (2022). FDA approves Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients.
- U.S. Food and Drug Administration. (2021). Cyanokit hydroxocobalamin for injection: Prescribing information.
- Fennec Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
